Story perspectives

Eli Lilly’s retatrutide cuts weight 28%, A1c 1.9% in trials

6/8/2026

Summary

Lilly Reports Weightloss

Eli Lilly reported that 12 mg retatrutide caused a 28.3% weight loss (?70 lb) versus 2.2% with placebo in phase 3 TRIUMPH-1, with 45.3% achieving >=30% loss.
In TRANSCEND-T2D-1, retatrutide lowered A1c by up to 1.94% (12 mg) versus 0.81% with placebo and cut triglycerides by up to 41%.
Urinary-tract infections occurred in 7.5%–8.8% of retatrutide users versus 5% with placebo, and discontinuations were 4.1%–11.3% in TRIUMPH-1 and 2.2%–5.1% in TRANSCEND-T2D-1.

Summary

Lilly Sets Record

Analysts at BMO Capital Markets and William Blair called retatrutide’s weight-loss results a new standard and record-breaking, boosting investor optimism for Eli Lilly.
Foundayo is the only oral GLP-1 therapy that can be taken without food or water restrictions, targeting menopausal women with weight gain.
Over 5,800 participants are enrolled in four TRIUMPH studies, with Eli Lilly set to present longer-term Mounjaro data at the upcoming ADA scientific sessions.

Summary

Pfizer Acquires Metsera

Pfizer bought Metsera for $10 billion, acquiring the experimental obesity drug berobenatide.
High weekly dosing cut weight ~16 % after 60 weeks and a maintenance schedule yielded ~12 % placebo-adjusted loss after 28 weeks.
A monthly-dose study showed 21 % discontinuations and higher nausea, vomiting and diarrhea versus Zepbound.
Roche’s Carmot deal added enicepatide (CT-388), which achieved 18 %–22.5 % placebo-adjusted loss but a modestly worse side-effect profile, prompting analysts to label it a me-too option.

Summary

Lilly Cuts Apnea

A Phase 3 trial found weekly retatrutide injections cut moderate-to-severe sleep apnea severity by 60.6 % in obese adults.
The study also showed knee osteoarthritis pain fell up to 73.1 % in drug-treated participants.
Results were presented at the American Diabetes Association conference in New Orleans.
2 % of diabetes patients on the lowest dose had major adverse cardiovascular events, not deemed drug-related.
Lilly said the data help retatrutide outpace Novo Nordisk and complement Zepbound.

1 of 4

Lilly Reports Weightloss

Eli Lilly reported that 12 mg retatrutide caused a 28.3% weight loss (?70 lb) versus 2.2% with placebo in phase 3 TRIUMPH-1, with 45.3% achieving >=30% loss.
In TRANSCEND-T2D-1, retatrutide lowered A1c by up to 1.94% (12 mg) versus 0.81% with placebo and cut triglycerides by up to 41%.
Urinary-tract infections occurred in 7.5%–8.8% of retatrutide users versus 5% with placebo, and discontinuations were 4.1%–11.3% in TRIUMPH-1 and 2.2%–5.1% in TRANSCEND-T2D-1.

1 / 4